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ABSTRACT 23 
Previous work on the subclones within Escherichia coli ST131 predominantly involved 24 
isolates from Western countries. This study assessed the prevalence and antimicrobial 25 
resistance attributed to this clonal group. A total of 340 consecutive, nonduplicated urinary E. 26 
coli isolates originating from four clinical laboratories in Hong Kong in 2013 were tested. 27 
ST131 prevalence among the total isolates was 18.5% (63/340) and was higher among 28 
inpatients isolates (23.0%) than outpatient isolates (11.8%, P<0.001); and higher among 29 
isolates from patients aged ≥65 years than from patients aged 18-50 years and 51-64 years 30 
(25.4% vs. 2.4% and 4.0%, respectively, P<0.001). Of the 63 ST131 isolates, 43 (68.3%) 31 
isolates belonged to the H30 subclone, whereas the remaining isolate belonged to H41 (n=17), 32 
H54 (n=2) and H22 (n=1). All H30 isolates were ciprofloxacin-resistant of which 18.6% 33 
(8/43) belonged to the H30-Rx subclone. Twenty-six (41.3%) ST131 isolates were 34 
ESBL-producers of which 19 had blaCTX-M-14 (12 non-H30-Rx, two H30-Rx and five H41), 35 
six had blaCTX-M-15 (five non-H30-Rx and one H30-Rx) and one was blaCTX-M negative (H30). 36 
In conclusion, ST131 accounts for a large share of the antimicrobial-resistant E. coli isolates 37 
from geriatric patients. Unlike previous reports, ESBL-producing ST131 strains mainly 38 
belonged to non-H30-Rx rather than the H30-Rx subclone with blaCTX-M-14 as the dominant 39 
enzyme type.  40 
  41 
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INTRODUCTION 42 
The incidence of infections due to antimicrobial-resistant Escherichia coli is increasing 43 
worldwide (Barber et al., 2013). Resistance rates for cotrimoxazole, fluroquinolones and 44 
third generation cephalosporins, which are often used for empirical therapy, are now above 45 
the 15-20% threshold recommended for choosing first-line antimicrobial agents for empirical 46 
treatment in Hong Kong (Ho et al., 2007b; Ho et al., 2010). Discordant therapy may cause 47 
treatment failure, persistence and recurrence of infection leading to more patient morbidity 48 
and mortality (Barber et al., 2013; Shin et al., 2012). Emerging resistance in E. coli involves 49 
acquisition of resistance determinant by susceptible strain and the expansion of preexisting 50 
resistant clones (Naseer & Sundsfjord, 2011). ST131 is a highly successful E. coli clone 51 
which has received considerable attentions due to its wide geographic distribution, ability to 52 
cause a wide range of extra-intestinal infections and association with CTX-M β-lactamases 53 
and multidrug resistance (Nicolas-Chanoine et al., 2014).  54 
 55 
ST131 can be divided into different subclones by other typing methods, of which sequencing 56 
the type 1 fimbrial adhesion gene fimH is one widely used approach (Weissman et al., 2012). 57 
H30, designated according to the fimH30 variant is currently the most prevalent subclone of 58 
ST131 (Nicolas-Chanoine et al., 2014). Two studies involving whole genome sequencing of 59 
ST131 isolates collected from multiple countries came to the same conclusion that 60 
4 
 
fluroquinolone resistance within ST131 was confined almost entirely to the H30 subclone and  61 
that CTX-M-15 producers clustered within a nested subclone, designated as H30-Rx (Petty et 62 
al., 2014; Price et al., 2013). Reported prevalence of H30 and H30-Rx among ST131 isolates 63 
ranged 66.7%-95.8% and 16.9%-66.2%, respectively, depending on the isolate sources and 64 
selection criteria (Banerjee et al., 2013b; Peirano et al., 2014; Peirano & Pitout, 2014; Price 65 
et al., 2013). Majority of the ST131 isolates that have been tested for the H30 and H30-Rx 66 
subclones were collected from North America and Europe; relatively few isolates were from 67 
Asia (Banerjee et al., 2013a; Banerjee et al., 2013b; Colpan et al., 2013; Johnson et al., 2013; 68 
Johnson et al., 2014; Peirano et al., 2014; Tchesnokova et al., 2013). Additionally, few 69 
studies have assessed the association of host factors with the two ST131 subclones (Banerjee 70 
& Johnson, 2014). Here, we used an unselected collection of urinary E. coli isolates from 71 
four laboratories in Hong Kong to evaluate the relationship between patient demographics, 72 
antimicrobial-resistant phenotypes, ST131 and its major subclones. 73 
 74 
METHODS 75 
Study design. A total of 340 non-duplicated, urinary E. coli isolates were studied. The 76 
isolates were consecutive single-patient E. coli isolates from four clinical microbiology 77 
laboratories in Hong Kong over a two week period, from May to June 2013. The laboratories 78 
together served about a quarter of the Hong Kong populations in different geographic 79 
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districts. The inclusion criteria were: (1) patient age 18 years or above, (2) mid-stream urine 80 
specimen, and (3) significant growth at ≥105 CFU/ml. Patient identities was kept anonymous. 81 
The following information was provided by the submitting laboratories: sex, age, date of 82 
collection and patient location (outpatient or inpatient). One isolate per patient was included.  83 
 84 
Microbiological methods. The VITEK GNI system (bioMerieux Vitek Inc., Hazelwood, MO) 85 
was used for bacterial identification. Antibiotic susceptibilities were tested by the disc 86 
diffusion method using Mueller-Hinton agar (Oxoid, Basingstoke, UK) and interpreted 87 
according to the Clinical and Laboratory Standard Institute. All antibiotic discs were obtained 88 
commercially (BBL, Becton Dickinson, Cockeysville, MD, USA). The double disk synergy 89 
test was used for detection of extended-spectrum β-lactamases (ESBL) (Ho et al., 2010). The 90 
susceptibility testing of all isolates were performed in a central laboratory at the University of 91 
Hong Kong. On each day of testing, standard strains (ATCC 25922 and 35218) were included 92 
as quality controls. For each isolate, the resistance score was the number of antimicrobials 93 
(including ampicillin, amoxicillin-clavulanate, cefuroxime, ceftriaxone, ertapenem, nalidixic 94 
acid, ciprofloxacin, co-trimoxazole, gentamicin, nitrofurantoin and fosfomycin which were 95 
chosen to represent 11 classes) for which it exhibited resistance (including both intermediate 96 
and resistant categories).    97 
 98 
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Molecular studies. PCR assays were used to assign the E. coli isolates to phylogroups A, B1, 99 
B2, C, D, E and F (Clermont et al., 2013). Phylogroup B isolates were investigated for ST131 100 
status by PCR assays targeting SNPs in mdh and gyrB (Johnson et al., 2009), and the O25b 101 
variant and SNPs in pabB (Clermont et al., 2009). A subset of the isolates were further tested 102 
by multilocus sequence typing (MLST) for confirmation (Wirth et al., 2006). 103 
ST131-associated O serotype, fimH subtype and the H30-Rx subsubclone were determined by 104 
established methods (Banerjee et al., 2013b; Clermont et al., 2007; Weissman et al., 2012). 105 
The blaCTX-M genes were detected by PCR and sequencing using primers with specificity for 106 
the CTX-M subgroups (blaCTX-M1G, blaCTX-M2G, blaCTX-M8G, blaCTX-M9G, and blaCTX-M25G) (Ho et 107 
al., 2007a; Ho et al., 2012). Alleles were assigned by sequening the full length of blaCTX-M as 108 
previously described (Ho et al., 2012).  109 
 110 
Statistical analysis. The Chi-square, Fisher’s exact test or Student’s t-test were used for 111 
statistical analysis. Univariate and multivariate analyses were used to assess risk factors 112 
associated with ST131 subclones. The following parameters were included in the multivariate 113 
analysis: age, sex, laboratory source, and patient care location. The values of parameters are 114 
given as mean (± standard deviation) where appropriate. A two-tailed P value of <0.05 was 115 
considered significant. All analyses were performed using statistical software (SPSS, version 116 
14.0; SPSS Inc; Chicago, IL). 117 
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RESULTS 118 
Patient demographics 119 
A total of 340 urinary isolates were included in the study; 204 (60.0%) from inpatients, 136 120 
(40.0%) from outpatients; 259 (76.2%) from females and 81 (23.8%) from males. Each 121 
laboratory contributed 82 to 89 isolates. Overall, 50 (14.7%) were obtained from patients 122 
aged 18-50 years, 58 (17.1%) from patients aged 51-64 years and 232 (68.2%) from patients 123 
aged ≥65 years. The patients had mean age of 69.7 ± 17.3 years. 124 
 125 
Distribution of phylogroups and ST131 by patient sources 126 
Phylogroup B2 predominated among the isolates with similar frequencies among isolates 127 
from different age groups (62.1%-66.0%) and among inpatients (63.7%) and outpatients 128 
(63.2%) isolates (Table 1). Allele-specific PCR assays targeting mdh and gyrB identified 63 129 
isolates as ST131 of which 45 isolates were also positive for O25b and pabB. One isolate was 130 
pabB positive and mdh-negative, gyrB-positive. MLST confirmed the isolate as ST131. 131 
Another 22 isolates were randomly chosen for MLST and all were confirmed to be ST131. 132 
The prevalence of ST131 among all urinary isolates was 18.5% (63/340) overall, but this 133 
varied according to isolate sources (Table 1). The prevalence of ST131 was higher among 134 
isolates from patients aged ≥65 years (25.4%) than the other age groups (3.4%-4.0%), and 135 
higher among inpatients (23.0%) than in outpatients (11.8%). Of the 63 ST131 isolates, 45 136 
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(71.4%) were serogroup O25b, 17 (27.0%) were serogroup O16 and one (1.6%) was 137 
O-non-typeable. Forty-three (68.3%) ST131 isolates belonged to the H30 subclone, whereas 138 
the remaining 20 isolates belonged to H41 (n=17), H54 (n=2) and H22 (n=1). All H30 139 
isolates were ciprofloxacin-resistant and 18.6% (8/43) of H30 isolates belonged to the 140 
H30-Rx subclone. In general, serogroup O25b isolates were of H30 (93.3%, 42/45) subclone 141 
and serogroup O16 were of H41 subclone (100%, 17/17). The frequency of H30 subclone 142 
was higher among patients aged ≥65 years and inpatients while those for H41 and other fimH 143 
subtypes were similar among the patient subsets. In multivariate analysis, aged ≥65y was the 144 
only factor significantly associated with ST131 (OR 8.9, 95% CI 3.1-25.1, P<0.001), H30 145 
(OR 7.3, 95% CI 2.2-24.1, P=0.001) and H41 (OR 7.9, 95% CI 1.04-60.6, P=0.046). 146 
 147 
Distribution of antibiotic resistance by ST131 status 148 
Among ST131 isolates, resistance rates for 8 of the 11 antimicrobials were high, ranging 149 
from 33.3% to 87.3% while those for nitrofurantoin (1.6%) and fosfomycin (1.6%) were rare. 150 
All isolates including all ST131 subclones were susceptible to ertapenem. ST131 isolates 151 
were significantly more likely than non-ST131 isolates to be resistant to ampicillin (87.3% vs. 152 
67.9%, respectively), amoxicillin-clavulanate (33.3% vs. 18.8%), cefuroxime (41.3% vs. 153 
20.9%), nalidixic acid (100% vs. 69.0%), ciprofloxacin (71.4% vs. 32.5%) and gentamicin 154 
(38.1% vs. 25.6%), and to be ESBL-producers (41.3% vs. 18.8%). Resistance rates among 155 
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H30 and H41 isolates were similar except for resistance to ciprofloxacin which is 156 
substantially higher among H30 isolates (100% for H30 vs. 11.8% for H41, P<0.001). The 157 
resistance score was highest for H30 isolates (5.1±2.0), followed by H41 isolates (3.5±1.4) 158 
and non-ST131 isolates (3.0±2.4). Within H30 isolates, resistance score for H30-Rx (4.9 ± 159 
2.7) and non-H30-Rx (5.1 ± 1.8) isolates were similar (P = 0.737).  160 
 161 
Rates of ESBL production, and ciprofloxacin, cotrimoxazole and gentamicin resistance were 162 
similar among isolates form different age groups. ST131 accounted for 33.3%, 33.3%, 25.3% 163 
of all ESBL-producing, ciprofloxacin-resistant, and gentamicin-resistant E. coli populations, 164 
respectively. In contrast, prevalence of ST131 among the antimicrobial-sensitive counterparts 165 
were significantly lower (P<0.05 for all comparisons), being 14.1% for ESBL-negative 166 
isolates, 8.8% for ciprofloxacin-sensitive isolates and 15.9% for gentamicin-sensitive isolates. 167 
The prevalence of ST131 among cotrimoxazole-resistant (17.4%) and -sensitive (19.2%) 168 
isolates was similar. Stratification by age groups revealed that there were variations in the 169 
resistant populations attributed to ST131 (Fig. 1). Among the ST131 isolates, 26 (41.3%) 170 
were ESBL-producers. PCR and sequencing showed that 19 had blaCTX-M-14 (12 non-H30-Rx, 171 
two H30-Rx and five H41), six had blaCTX-M-15 (five non-H30-Rx and one H30-Rx) and one 172 
was blaCTX-M negative (H30).  173 
 174 
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DISCUSSION 175 
We evaluated 340 E. coli urine isolates, collected from four laboratories in 2013 for the 176 
ST131 clonal group and its subclones. The prevalence of ST131 among total E. coli isolates 177 
(18.5%) is concordant with other studies in the United State (17%-27%) and Europe 178 
(12%-22%) (Nicolas-Chanoine et al., 2014). Our findings showed that the prevalence of 179 
ST131 and its H30 subclone were higher among older age, inpatients and 180 
antimicrobial-resistant isolates. These findings indicated that expansion of ST131 is an 181 
important mechanism of increased antimicrobial resistance in the geriatric population. The 182 
reason for the higher prevalence of ST131 among geriatric patients is not clear but could 183 
possibly be related to selection from over-prescription of broad-spectrum antimicrobials 184 
(third generation cephalosporins, fluroquinolones), institutional acquisition from exposure in 185 
old age homes and hospitals, and underlying comorbidities (Ho et al., 2014). In previous 186 
studies, approximately 25% of hospitalized patients and elderly residents of long-term care 187 
facilities were found to carry ST131 in their feces (Banerjee & Johnson, 2014), comparing 188 
with <5% among healthy young adults (Kudinha et al., 2013; Leflon-Guibout et al., 2008); 189 
suggesting institutions may pose risk for ST131 transmission. However, a recent study found 190 
that only 2.1% of 240 residents from 11 nursing homes in Germany had fecal carriage of 191 
ST131 (Arvand et al., 2013).  192 
 193 
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We found that H30 comprised 68.3% of all ST131 isolates which is lower than the 194 
proportions reported for unselected clinical isolates from the United States (87.3%) and 195 
France (86.5%) (Lafolie et al., 2014). The prevalence of H30-Rx subclone among our H30 196 
isolates was 18.6%, which is substantially lower than the >70% among H30 ST131 isolates 197 
preselected by specific resistance phenotypes (Banerjee et al., 2013b; Peirano et al., 2014). 198 
H30-Rx described previously among isolates from Europe and North America was almost 199 
always ESBL-positive and had CTX-M-15 (Peirano et al., 2014; Petty et al., 2014; Price et 200 
al., 2013). Here, only three of the eight H30-Rx isolates were ESBL-producers. Unlike 201 
previous reports (Peirano et al., 2014; Petty et al., 2014; Price et al., 2013), ESBL-producing 202 
ST131 strains in the present study mainly belonged to non-H30-Rx rather than the H30-Rx 203 
subclone. Among all ST131 subclones, CTX-M-14 was the predominant ESBL found. 204 
Plasmid IncF family played a major role in the dissemination of CTX-M-15 in Europe and 205 
the United States (Nicolas-Chanoine et al., 2014). In Asia, IncF plasmids were found to more 206 
often carry CTX-M-14 instead of CTX-M-15 (Ho et al., 2007a; Nicolas-Chanoine et al., 207 
2014). Among ST131 isolates, IncF plasmids carrying CTX-M-14 have been reported from 208 
Hong Kong, mainland China and South Korea (Ho et al., 2012; Nicolas-Chanoine et al., 209 
2014). In Japan, CTX-M-14 was detected in 44% and 73% of ESBL-producing ST131-O25b 210 
and ST131-O16 isolates, respectively, comparing with 18% and 8% for CTX-M-15, 211 
respectively. (Matsumura et al., 2012).  212 
12 
 
 213 
In summary, this study found that antimicrobial-resistant E. coli from geriatric patients are 214 
substantially more likely to be caused by ST131 than those from younger patients, and that 215 
the H30 and H41 subclones possess certain resistance traits different from those reported in 216 
other locales.  217 
  218 
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Table 1. Distribution of phylogroups and ST131 among 340 urinary E. coli isolates 337 
Categories  No (column %) by age group   No (column %) by source  
 n 18-50y (n=50) 51-64y (n=58) ≥65y (n=232) P  Inpatients (n=204) Outpatients (n=136) P 
ST131          
H30 subclone 43 1 (2.0) 2 (3.4) 40 (17.2) 0.001  31 (15.2) 12 (8.8) 0.083 
H41 subclone 17 1 (2.0) 0 (0) 16 (6.9) 0.056  13 (6.4) 4 (2.9) 0.155 
Others* 3 0 (0) 0 (0) 3 (1.3) 0.494  3 (1.5) 0 (0) 0.155 
Subtotal 63 2 (4.0) 2 (3.4) 59 (25.4) <0.001  47 (23.0) 16 (11.8) <0.001 
H30-Rx 8 0 (0) 1 (1.7) 7 (3.0) 0.417  6 (2.9) 2 (1.5) 0.381 
* Including H54 (two isolates) and H22 (one isolate). 338 
 339 
 340 
 341 
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Fig 1. Antimicrobial-resistant E. coli populations attributed to ST131 according to age groups. 342 
The P values are indicated for between age groups comparison. 343 
 344 
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 346 
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 348 
 349 
